Drug intelligence / Profile preview

netivudine

Development stage: Phase 3
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Netivudine is an orally active nucleoside analogue, specifically a thymidine analogue, with potent and specific antiviral activity against varicella-zoster virus (VZV). It has been shown to be approximately seven times as potent as acyclovir in vitro. Netivudine acts by inhibiting viral DNA synthesis after phosphorylation by viral thymidine kinase, leading to chain termination during DNA replication. It was investigated primarily for the treatment of herpes zoster (shingles), chickenpox, and HIV infections. Clinical trials reached up to Phase III for these indications[1][2][3][4][7].

Brand names: Zonavir
Other names: NETIVUDINEnetivudinanetivudinum5-propynyl-araU1-beta-D-Arabinofuranosyl-5-(1-propynyl)uracil

Targets

Herpesvirus DNA polymerase

Beyond the preview

Go deeper on netivudine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on netivudine.

Explore the full profile